On February 4, 2019, InventaBioTech Inc. announced that James Garvin submitted his resignation from his positions with the Company as Chief Executive Officer and member of the Board of Directors, effective immediately. On February 4, 2019, in connection with the CEO Resignation, the Board appointed Mr. Steven W. Charest as Interim Chief Executive Officer (“Interim CEO”) and a member of the Board, effective immediately, and approved the Company's entrance into an employment agreement with Mr. Charest (the “Charest Employment Agreement”). Steven W. Charest, age 54, currently serves as a managing director and a partner at Divine Capital Markets, LLC, a New York based broker/dealer investment bank, providing strategic advisory, capital raise and M&A services to technology-enabling and life science businesses.

Mr. Charest will serve as Interim CEO until a permanent CEO is employed by the Company, and in any case, for a maximum term of six months, commencing on February 4, 2019. On February 4, 2019, in connection with CFO Financial changing its staffing with regard to the services it provides to the Company, Mr. Zucker submitted his resignation from his position with the Company as Chief Financial Officer, effective immediately. On February 4, 2019, the Company and CFO Financials agreed to appoint Keith George, an employee of CFO Financial, as the Company's Chief Financial Officer.

Mr. George, has served as the Chief Financial Officer and Financial Operations Principal for several registered broker-dealers which are clients of CFO Financial since 2013.